Form 8-K Deciphera Pharmaceutical For: Nov 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Deciphera Pharmaceuticals (DCPH) Misses Q3 EPS by 9c
November 2, 2021 4:33 PM EDTDeciphera Pharmaceuticals (NASDAQ: DCPH) reported Q3 EPS of ($1.37), $0.09 worse than the analyst estimate of ($1.28). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $23.36 million.
For earnings history and earnings-related data on Deciphera Pharmaceuticals (DCPH) click here.
... More